Catalyst Wire Dossier Catalyst Wire Dossier

CD40.RBDv Bivalent COVID-19 Vaccine

CD40.RBDv bivalent vaccine against SARS-CoV-2
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CD40.RBDv Bivalent COVID-19 Vaccine, covering 2025-04-25 to 2025-04-25. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers. [Phase 1, Phase 2]

See pricing